Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on March 3, 2022, covering the event date of February 25, 2022. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Capital Market under the symbol "PHIO".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
On February 25, 2022, the Company received a Notification Letter from The Nasdaq Capital Market stating it was not in compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Rule. The non-compliance occurred because the Company's common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the stock.
Outlook, Management Commentary, and Risks
- Compliance Period: The Company has an initial 180-calendar day period, until August 24, 2022, to regain compliance.
- Path to Compliance: Compliance will be achieved if the bid price closes at $1.00 per share or more for a minimum of 10 consecutive business days before the deadline.
- Management Action: Management intends to actively monitor the closing bid price and evaluate available options to regain compliance.
- Risks: Failure to regain compliance within the specified timeframe could result in delisting from The NASDAQ Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of PHIO stock to assess proximity to the $1.00 threshold.
- Monitor the stock's performance over the next 10 consecutive business days to determine if compliance is achieved.
- Review future filings for updates on the Company's strategy to maintain the minimum bid price.
- Check for any subsequent notices from Nasdaq regarding the extension or termination of the compliance period.